Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
Clinical trial NCT04410445 · TERMINATED
Trial details
- NCT number
- NCT04410445
- Sponsor
- Nektar Therapeutics
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-27
- Primary completion
- 2022-09-22
- Enrollment
- 765
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.